Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020095104 - HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF

Publication Number WO/2020/095104
Publication Date 14.05.2020
International Application No. PCT/IB2019/001178
International Filing Date 04.11.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
A61P 43/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C07K 16/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors ; ; against growth regulators
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
Applicants
  • LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. [CH]/[CH]
  • CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS [CH]/[CH]
Inventors
  • RITTER, Gerd
  • DUNN, Steven
Priority Data
62/755,84005.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
(FR) ANTICORPS SPÉCIFIQUES DE TGF-β3 VARIANTS ET PROCÉDÉS ET UTILISATIONS ASSOCIÉS
Abstract
(EN)
Antibodies, particularly humanized antibodies and variant antibodies and fragments thereof, which bind to transforming growth factor beta 3 (ΤΟΡ-β3) are provided, recognizing human and mouse ΤΟΡ-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1or ΤΟΡ-β2. Humanized and variant antibodies are provided which specifically recognize and neutralize ΤΟΡ-β3 and are useful in the diagnosis and treatment of conditions associated with activated or elevated ΤΟΡ-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF^3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and in therapy in combination with chemotherapeutic s, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by antibodies hereof, including antibodies 1901-1 A, 1901-1B, 1901-1C and 1901-1D whose sequences are provided herein.
(FR)
L'invention concerne des anticorps, en particulier des anticorps et des anticorps variants et des fragments de ceux-ci, qui se lient au facteur de croissance transformant bêta 3 (TGP-β3), reconnaissant le TGP-β3 humain et murin, particulièrement des anticorps et des fragments qui ne reconnaissent pas ou ne se lient pas à TGF‑β1 ou TGF-β2. L'invention concerne des anticorps humanisés et variants qui reconnaissent et neutralisent spécifiquement le TGF-β3 et sont utiles dans le diagnostic et le traitement d'affections associées à un TGF-β3 activé ou élevé, notamment le cancer, et pour moduler des cellules immunitaires et de la réponse immunitaire, notamment la réponse immunitaire au cancer ou aux antigènes du cancer, et dans des affections fibrotiques. Ces anticorps anti-ΤGF-β3, des régions variables ou des séquences de domaines CDR de ceux-ci, ainsi que des fragments de ceux-ci peuvent également être utilisés dans une thérapie médiée par des cellules lymphoïdes, médiée par des lymphocytes T et dans une thérapie en combinaison avec des agents chimiothérapeutiques, immunomodulateurs ou anticancéreux et/ou d'autres anticorps ou fragments de ceux-ci. Des anticorps sont illustrés par des anticorps ici décrits, y compris des anticorps 1901-A, 1901-1B, 1901-1C et 1901-1D dont les séquences sont fournies ici.
Latest bibliographic data on file with the International Bureau